Straightforward conversion of Decoquinate (cas 18507-89-6) into inexpensive tractable new derivatives with significant antimalarial activities

Add time:09/08/2019    Source:sciencedirect.com

As part of a programme aimed at identifying rational new triple drug combinations for treatment of malaria, tuberculosis and toxoplasmosis, we have selected quinolones as one component, given that selected examples exhibit exceptionally good activities against the causative pathogens of the foregoing diseases. The quinolone Decoquinate (cas 18507-89-6) (DQ), an old and inexpensive coccidiostat, displays anti-malarial activity in vitro against Plasmodium falciparum (Pf). However, because of its exceedingly poor solubility in water or organic solvents, development of DQ as a drug is problematical. We have therefore converted DQ in straightforward fashion into tractable new derivatives that display good activities in vitro against chloroquine-sensitive NF54 and multidrug-resistant K1 and W2 Pf, and relatively low toxicities against human fibroblast cells. The most active compound, the N-acetyl derivative 30, is 5-fold more active than DQ against NF54 and K1 and equipotent with DQ against W2. It possesses an activity profile against all strains comparable with that of the artemisinin derivative artesunate. Overall, this compound and the other accessible and active derivatives serve as an attractive template for development of new and economic lead quinolones.

We also recommend Trading Suppliers and Manufacturers of Decoquinate (cas 18507-89-6). Pls Click Website Link as below: cas 18507-89-6 suppliers

Prev:Original articleDecoquinate (cas 18507-89-6) derivatives: A new class of potent antischistosomal agents against Schistosoma japonicum
Next:Research ArticleNanoparticle formulations of Decoquinate (cas 18507-89-6) increase antimalarial efficacy against liver stage Plasmodium infections in mice)